Actinogen Medical Limited (ATGGF)

Market Cap	126.34M
Revenue (ttm)	3.60M
Net Income (ttm)	-9.66M
Shares Out	n/a
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,500
Average Volume	84,086
Open	0.0200
Previous Close	0.0400
Day's Range	0.0200 - 0.0200
52-Week Range	0.0100 - 0.0400
Beta	1.19
RSI	37.86
Earnings Date	Nov 24, 2025

About Actinogen Medical

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: ATGGF

Financial Performance

In 2025, Actinogen Medical's revenue was 5.49 million, a decrease of -44.73% compared to the previous year's 9.93 million. Losses were -14.73 million, 12.9% more than in 2024.

Financial numbers in AUD